ESTRO 2022 - Abstract Book

S1149

Abstract book

ESTRO 2022

With a median follow-up of 18 months (range 1-95), no patients presented acute or late toxicities higher than grade 2, except for one case of grade 4 bone toxicity (fracture) 26 months after SBRT. This patient was treated for a sacral lesion with 40 Gy, having previously received 45 Gy on the pelvic nodal area. One year- and 2 years-LC were 84.0% and 76.3% respectively (Image 1), while the 1 year- and 2 years-OS were 81.6% in both cases. The overall clinical response rate was 70.8% with a complete response rate of 65.4%.

Regarding QoL, no statistically significant difference was found between the baseline and follow-up values: the median CLAS1, CLAS2 and CLAS3 was 6 (range 4-10) at baseline for each category, and still 6 (range 3-10) one month after SBRT.

Conclusion According to this preliminary experience, in-site SBRT retreatment for recurrent gynaecological cancer could be considered a quite feasible and safe treatment without any short-term QoL impairment.